Stability of Essential Drugs in Tropical Climates: Zimbabwe - EDM Research Series No. 013
(1994; 86 pages) View the PDF document
Table of Contents
View the documentAbbreviations
View the document1. Summary
Open this folder and view contents2. Introduction
Open this folder and view contents3. Study design and methods
View the document4. Results
Open this folder and view contents5. Discussion
Open this folder and view contents6. Conclusions and recommendations
View the documentReferences
Close this folderAnnexes
Close this folderAnnex 1: Detailed results for each drug
View the document1.1 Amoxycillin capsules
View the document1.2 Ampicillin capsules
View the document1.3 Acetylsalicylic acid tablets
View the document1.4 Doxycycline capsules
View the document1.5 Ferrous sulfate tablets
View the document1.6 Phenoxymethylpenicillin tablets
View the document1.7 Tetracycline capsules
View the document1.8 Retinol tablets
View the document1.9 Epinephrine injection
View the document1.10 Ampicillin injection
View the document1.11 Benzylpenicillin injection
View the document1.12 Ergometrine injection
View the document1.13 Procaine penicillin injection
View the documentAnnex 2: Validation of laboratory results
 

1.6 Phenoxymethylpenicillin tablets

SHELF LIFE

Manufacturer A:4 years

ASSAY METHOD

Spectrophotometric method, BP 1988 p. 985. Contents of 20 capsules mixed; measured three times; mean taken.

ASSAY LIMITS

92.5 - 107.5% (BP)

SAMPLES OBTAINED

Manufacturer A

GMS samples

no.

%

Total

14

100

Harare

2

14

Bulawayo

12

86

Facility samples

   

Total

59

100

Age > 50 % SLife

4

7

Facility type = PCH

44

75

Climate = hot

50

85

Transport = slow

41

89

Longitudinal Series

   

Total

7

100

SUMMARY ASSAY RESULTS

GMS samples

Manufacturer A

Mean age (mths)

 

7.3

Mean assay

 

99.3%

95% CL

96.9-101.7%

No. and % fail

0

0%

Facility samples

Manufacturer A

Mean age (mths)

 

12.5

Mean assay

 

104.0%

95% CL

103.0 - 104.9%

No. and % fail

8

14%

No. and % low fail

0

0%

No, and % high fail

8

14%

Longitudinal series

at Manuf .

at GMS

at facility

Mean age (mths)

 

0

 

8.3

 

16.5

Mean assay

 

100.2%

 

99.2%

 

103.7%

95% CL

99.7-100.7%

96.1- 102.2%

101.9- 105.6%

No, and % fail

0

0%

0

0%

0

0%

 

Mean interval (mths)

8.2

 

Mean loss (-) or gain (+)

+4.8%

 

95% CL for loss/gain

+.06 to +9.0%


Figure 1 - Results of facility samples

Findings:

a) No expired samples found.

b) All 14 GMS samples were within assay limits (mean 99.3%).

c) Eight of 59 facility samples (14%) failed, all above the upper limit (maximum value 113.9%).

d) No loss of potency was found in seven GMS/facility sample pairs.

e) No initial quality problem was seen.

f) The high values in facility sample potency are not therapeutically significant.

g) No sign of instability, however samples were in the early part of a long shelf-life (mean age 12.5 months, maximum age 33.3 months),

h) Turnover usually fast at facility level (mean storage time 5.4 months, maximum 21.1 months).

to previous section to next section
 

Last updated: May 3, 2013